ImmunoCellular Therapeutics (IMUC) Reports Q4 Loss of $1.23/Share
Tweet
Share
E-mailGet Alerts IMUC Hot Sheet
Join SI Premium – FREE
ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($1.23), versus ($7.89) reported last year.
For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
- Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
- Etsy upgraded to buy at BofA on durable growth, buyback potential
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
